Healthcare Scheme to Overcome Financial Burden Associated with Chemoradiation Therapy in Head and Neck Cancer Patients: A Retrospective Single Centre Study

Head and neck cancer (HNC) is third highest prevalent cancer among Indian which constitutes about 25–30% of all the cancer in India. Further, out-of-pocket expenditure (OOPE) covers around 67% of total healthcare expenditure and direct medical cost is key factor responsible for raised OOPE in India. Thus, we aimed to quantify total direct medical cost and OOPE associated with HNC management among HNC patients using “Ayushman Bharat Arogya Karnataka scheme” (ABArK scheme). A retrospective study was conducted for the duration of 6 months to collect the data related to total direct medical cost, coverage of “ABArK Scheme” and OOPE of past 2 years of HNC patients. The data of HNC patients above 18 years of age utilizing “ABArK scheme” were included in the study whereas data of patients utilizing other healthcare schemes and incomplete data on target schemes were excluded. A total of 196 patients (54.1%) utilized the “ABArK Scheme” out of 362 HNC patients treated in past 2 years. Among 196 patients, males (76.5%) were predominant over females (23.5%) with the mean age of 53.60 ± 11.58 years. We found that INR 17,370,279 as the total direct medical expenditure for the management of HNC patients of which around 87.465% was covered by “ABArK Scheme” minimizing the OOPE up to INR 3,297,970. Thus, Introduction and implementation of novel healthcare policies like “ABArK Scheme” can counteract financial burden of cancer management by significantly reducing OOPE which could be milestone achievement for the low-middle income countries like India.